As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of ranibizumab in the treatment of ocular disorders.
This review discusses the recent TGA-approved indication for ranibizumab, retinopathy of prematurity, as well overviewing the efficacy and safety of this anti-vascular endothelial growth factor agent. Recommendations are included from Dr Paul Beaumont, a prominent medical retinal specialist in Australia.
Please login below to download this issue (PDF)